Research Institute: South Australian Health and Medical Research Institute
Amount granted: $2.5 million
Year granted: 2018
A new research facility will be housed within SAHMRI and the University of Adelaide’s adjacent Adelaide Health and Medical Sciences building will be established with a $2.5M grant from ACRF. It will target five critically important cancer streams – chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, prostate cancer and colorectal cancer.
“The ACRF Centre for Integrated Cancer Systems Biology will be a state-of-the-art facility bringing together next generation technologies to transform patient outcomes through the delivery of targeted and personalised cancer therapy,” Professor Hughes said.
It will build on the work of several previously funded ACRF centres in Adelaide and harness an existing collaborative relationship with the Royal Adelaide Hospital (RAH) which is co-located in Adelaide BioMed City.
SAHMRI’s Cancer Theme Leader, Professor Tim Hughes, thanked the Australian Cancer Research Foundation (ACRF) for the $2.5 million grant which was announced this evening.
“My colleagues and I are excited by this opportunity to build on South Australia’s proud history of ground-breaking translational research for the benefit of cancer patients globally.”
“ACRF grants are competitively assessed and the success of the SAHMRI application is a testament to the high quality of cancer research and treatment in South Australia. The deeper understanding of cancer biology that will result from this grant will improve the outcomes for cancer patients throughout Australia and beyond.” Professor Ian Brown, CEO of ACRF, said.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.